Trials / Unknown
UnknownNCT03923179
Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
The Efficacy and Safety of Pyrotinib Combined With Etoposide in HER2-positive Advanced Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | Pyrotinib, 400mg qd |
| DRUG | Etoposide | Etoposide, 50mg，qd,d1-21,Q4W |
Timeline
- Start date
- 2019-04-19
- Primary completion
- 2021-04-01
- Completion
- 2021-12-31
- First posted
- 2019-04-22
- Last updated
- 2019-04-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03923179. Inclusion in this directory is not an endorsement.